Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
Leo
Roberto
R
Razzini
Cinzia
C
Di Lorenzo
Giorgio
G
Bianchi
Francesco
F
Tesauro
Manfredi
M
Zanasi
Marco
M
Siracusano
Alberto
A
Romeo
Francesco
F
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000068180:Aripiprazole; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D003577:Cytochrome P-450 Enzyme System; D006220:Haloperidol